EUVIMEDEUVIMED entdecken
Crossref

Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program

C. Spencer Yost, Adil Daud, Michael A. Gropper

ICU Director · 2010

DOI: 10.1177/1944451610363596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ICU Director, 2010. Verfasst von C. Spencer Yost und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-2 (IL-2) is a cytokine that produces an in vivo immunostimulating effect when given systemically. This action may arise from stimulating the growth and expansion of cytotoxic T cells that in turn activate natural killer cells to attack tumors such as malignant melanoma and renal cell carcinoma. Therefore, administration of high-dose IL-2 can invoke an antitumor response in some patients. However, high-dose IL-2 induces severe and sometimes life-threatening toxicity, including vascular leak syndrome, hypotension, fever, and end-organ damage. Renal, hepatic, pulmonary, cardiac, and neurologic side effects have been described. Patients receiving IL-2 therefore require close monitoring to detect and treat life-threatening complications arising from treatment. The authors describe the steps taken to begin an IL-2 biotherapy program in a small ICU at a regional comprehensive cancer center. The addition of “elective” IL-2 admissions to the ICU has had a beneficial effect on stabilizing the daily census. In addition, it has brought a new cohort of patients who are highly appreciative of the care they receive and provides the nursing staff a new opportunity to develop expertise with cancer biotherapy.

Zitieren

APA

Yost, C. S., Daud, A., & Gropper, M. A. (2010). Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program. ICU Director. https://doi.org/10.1177/1944451610363596

Vancouver

Yost CS, Daud A, Gropper MA. Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program. ICU Director. 2010. doi:10.1177/1944451610363596

BibTeX
@article{Yost2010,
  author = {Yost, C. Spencer and Daud, Adil and Gropper, Michael A.},
  title = {Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program},
  journal = {ICU Director},
  year = {2010},
  doi = {10.1177/1944451610363596}
}
Kostenlos starten →